Aminopyrazinyl-2-carboxamides

In this review we focus on the discussion of those small molecules which are described not only to inhibit GSK-3P in a primary kinase assay, but also where there is pubhshed data on how the compounds influence the level of tau phosphorylation in either a cellular or in vivo system (see [55] for a broader review). This latter criterion narrows down the compounds for discussion considerably, to only nine distinct chemical sub-types, where two such series from AstraZeneca—3-aminopyrazinyl-2-carboxamides and oxindolequinazohnes—are reported for the first time. In addition to these there are two other inhibitor classes described in the hterature which will not be discussed in the course of this review sodium valproate [51], where there is conflicting data [52], and large molecules such as GSK-3 binding proteins (e.g. amongst others GSKIP or FRAT-1 [50,53]), which are beyond the scope of this focus on small molecules. 

---